T-CELL PROLYMPHOCYTIC LEUKEMIA
Clinical trials for T-CELL PROLYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new T-CELL PROLYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for T-CELL PROLYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo offers hope for Hard-to-Treat lymphomas
Disease control Recruiting nowThis early-stage study tests the safety of combining two drugs, ruxolitinib and duvelisib, in people with T- or NK-cell lymphoma that has come back or not responded to prior treatments. The goal is to find the best dose and see if the combination can control the disease. About 70…
Matched conditions: T-CELL PROLYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 09:29 UTC
-
New drug may prevent lymphoma relapse after transplant
Disease control Recruiting nowThis study tests whether the drug ruxolitinib can help prevent T-cell lymphoma from returning and reduce graft-versus-host disease (GVHD) after a stem cell transplant. About 44 adults with T-cell lymphoma who are in remission after transplant will take ruxolitinib as a maintenanc…
Matched conditions: T-CELL PROLYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated May 26, 2026 09:21 UTC